– USA, MI – OcuSciences, a medical device company developing ocular imagers to detect early disease by assessing retinal metabolic activity, today announced the addition of Dr. Michael Patane (Ph.D.) to its Board of Directors, bringing over 25 years of drug discovery and development experience, with a proven track record of leadership in startup, biotechnology and pharmaceutical companies.
About Dr. Michael Patane
Dr. Michael Patane served as the President of Mitobridge, Inc., a wholly-owned subsidiary of Astellas. In this role, he successfully oversaw all operations and played a pivotal role in shaping the company’s vision and strategy, ultimately leading to significant achievements, including a Series A financing of $45MM, a strategic alliance with Astellas totaling $30MM non-dilutive, and the company’s acquisition by Astellas for $450MM.
His experience extends beyond Mitobridge, having served as CSO of Eyegate Pharmaceuticals, Inc. where he focused on discovering and developing ocular therapeutics utilizing a proprietary iontophoresis system. Before Eyegate, Dr. Michael Patane held key positions such as Director of Global Discovery Chemistry at Novartis Institutes for Biomedical Research and Director of Medicinal Chemistry at Millennium Pharmaceuticals, where he led drug discovery efforts in the fields of oncology and metabolic diseases.
“OcuSciences is at a very exciting time in its history as it builds momentum around its novel and patented retinal disease detection modality,” said Dr. Michael Patane. “I am honored to join this Board and look forward to working with my fellow directors and senior management to help OcuSciences advance the development and commercialization of its transformative retinal imaging devices.”
About OcuSciences, Inc.
OcuSciences, Inc., is a commercial-stage biotechnology company developing retinal imagers to identify metabolic dysfunction occurring in the retina for the early detection of disease. Its flagship device, the OcuMet Beacon, has been developed to automatically and non-invasively assess retinal metabolic function by detecting the degree of flavoprotein fluorescence, a well-studied precursor to retinal cell death, in a patient’s eye. OcuSciences has shown preliminary clinical utility in several different disease states, including diabetic retinopathy, glaucoma, and age-related macular degeneration.
For more information: https://www.ocusciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
